Los Angeles Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-15,175
| Closed | -$170K | – | 1463 |
|
|
2017
Q3 | $170K | Hold |
15,175
| – | – | ﹤0.01% | 1262 |
|
|
2017
Q2 | $167K | Sell |
15,175
-1,600
| -10% | -$16K | ﹤0.01% | 1163 |
|
|
2017
Q1 | $164K | Buy |
16,775
+1,607
| +11% | +$16K | ﹤0.01% | 1110 |
|
|
2016
Q4 | $164K | Hold |
15,168
| – | – | ﹤0.01% | 1124 |
|
|
2016
Q3 | $155K | Buy |
+15,168
| New | +$165K | ﹤0.01% | 1184 |
|
|
2016
Q2 | – | Sell |
-10,548
| Closed | -$116K | – | 1315 |
|
|
2016
Q1 | $116K | Sell |
10,548
-1,225
| -10% | -$10.9K | ﹤0.01% | 1095 |
|
|
2015
Q4 | $108K | Hold |
11,773
| – | – | ﹤0.01% | 1105 |
|
|
2015
Q3 | $82K | Hold |
11,773
| – | – | ﹤0.01% | 1140 |
|
|
2015
Q2 | $116K | Hold |
11,773
| – | – | ﹤0.01% | 1183 |
|
|
2015
Q1 | $104K | Hold |
11,773
| – | – | ﹤0.01% | 1190 |
|
|
2014
Q4 | $103K | Buy |
11,773
+625
| +6% | +$5.06K | ﹤0.01% | 1093 |
|
|
2014
Q3 | $77K | Sell |
11,148
-940
| -8% | -$5.63K | ﹤0.01% | 1048 |
|
|
2014
Q2 | $64K | Sell |
12,088
-24,215
| -67% | -$118K | ﹤0.01% | 1182 |
|
|
2014
Q1 | $165K | Sell |
36,303
-160
| -0.4% | -$773 | ﹤0.01% | 1208 |
|
|
2013
Q4 | $184K | Sell |
36,463
-2,110
| -5% | -$10.2K | ﹤0.01% | 1221 |
|
|
2013
Q3 | $196K | Buy |
+38,573
| New | +$215K | ﹤0.01% | 1239 |
|
Los Angeles Capital Management's SCLN Position: Q4 2017 in Review
Los Angeles Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 15,175 shares — an estimated $170K sold.
Los Angeles Capital Management first reported a position in SCLN in Q3 2013 and held it in 16 quarters. The position peaked at $196K in Q3 2013. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Los Angeles Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Los Angeles Capital Management sold 15,175 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $170K.
- Los Angeles Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q3 2013 and held it in 16 quarters.
- Los Angeles Capital Management's Sciclone Pharmaceuticals Inc position peaked at $196K in Q3 2013.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Los Angeles Capital Management's 13F filing for Q4 2017, filed 5 Feb 2018.